Lapatinib and breast cancer: current indications and outlook for the future (Q37782086)

23 August 2017

Lapatinib and breast cancer: current indications and outlook for the future (English)

1 reference

23 August 2017

1 reference

Cynthia Moreira

1

1 reference

PubMed ID

20735304

23 August 2017

Virginia Kaklamani

series ordinal

2

1 reference

23 August 2017

1 August 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

8

1 reference

23 August 2017

1171-1182

1 reference

23 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

HER-2/neu signal transduction in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

The distinctive nature of HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Mechanisms of resistance to HER family targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Biologic and therapeutic role of HER2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Effects of food on the relative bioavailability of lapatinib in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Jumping higher: is it still possible? The ALTTO trial challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

The assessment and management of cancer treatment-related diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.113

21 January 2018

Identifiers

DOI

10.1586/ERA.10.113

1 reference

23 August 2017

1 reference

PubMed ID

20735304